Initial Development and Characterization of PLGA Nanospheres Containing Ropivacaine

Página do item simplificado
dc.contributor.authorMoraes, Carolina Morales
dc.contributor.authorde Matos, Angelica Prado
dc.contributor.authorde Lima, Renata
dc.contributor.authorRosa, Andre Henrique [UNESP]
dc.contributor.authorde Paula, Eneida
dc.contributor.authorFraceto, Leonardo Fernandes [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.contributor.institutionUniversidade Estadual de Campinas (UNICAMP)
dc.date.accessioned2014-05-20T15:27:39Z
dc.date.available2014-05-20T15:27:39Z
dc.date.issued2007-12-01
dc.description.abstractLocal anesthetics are able to induce pain relief by binding to the sodium channels of excitable membranes, blocking the influx of sodium ions and the propagation of the nervous impulse. Ropivacaine (RVC) is an amino amide, enantiomerically pure, local anesthetic largely used in surgical procedures, which present physico-chemical and therapeutic properties similar to those of bupivacaine but decreased toxicity and motor blockade. The present work focuses on the preparation and characterization of nanospheres containing RVC; 0.25% and 0.50% RVC were incorporated in poly(d,l-lactide-co-glycolide (PLGA) 50:50) nanospheres (PLGA-NS), prepared by the nanoprecipitation method. Characterization of the nanospheres was conducted through the measurement of pH, particle size, and zeta potential. The pH of the nanoparticle system with RVC was 6.58. The average diameters of the RVC-containing nanospheres was 162.7 +/- 1.5 nm, and their zeta potentials were negative, with values of about -10.81 +/- 1.16 mV, which promoted good stabilization of the particles in solution. The cytotoxicity experiments show that RVC-loaded PLGA-NS generate a less toxic formulation as compared with plain RVC. Since this polymer drug-delivery system can effectively generate an even less toxic RVC formulation, this study is fundamental due to its characterization of a potentially novel pharmaceutical form for the treatment of pain with RVC.en
dc.description.affiliationState Univ São Paulo, Dept Environm Engn, BR-18087180 Sorocaba, SP, Brazil
dc.description.affiliationUniv Estadual Campinas, Inst Biol, Dept Biochem, Campinas, SP, Brazil
dc.description.affiliationUnespState Univ São Paulo, Dept Environm Engn, BR-18087180 Sorocaba, SP, Brazil
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.description.sponsorshipConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.description.sponsorshipIdFAPESP: 06/00121-0
dc.description.sponsorshipIdFAPESP: 07/00127-0
dc.description.sponsorshipIdFAPESP: 06/05220-5
dc.format.extent455-461
dc.identifierhttp://dx.doi.org/10.1007/s10867-008-9094-z
dc.identifier.citationJournal of Biological Physics. Dordrecht: Springer, v. 33, n. 5-6, p. 455-461, 2007.
dc.identifier.doi10.1007/s10867-008-9094-z
dc.identifier.issn0092-0606
dc.identifier.orcid0000-0002-2042-018X
dc.identifier.urihttp://hdl.handle.net/11449/37595
dc.identifier.wosWOS:000259961000010
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofJournal of Biological Physics
dc.relation.ispartofjcr1.000
dc.relation.ispartofsjr0,353
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectRopivacainept
dc.subjectNanospherespt
dc.subjectPLGApt
dc.subjectDrug deliverypt
dc.titleInitial Development and Characterization of PLGA Nanospheres Containing Ropivacaineen
dc.typeArtigo
dcterms.licensehttp://www.springer.com/open+access/authors+rights?SGWID=0-176704-12-683201-0
dcterms.rightsHolderSpringer
unesp.author.lattes5228846314663888[4]
unesp.author.orcid0000-0002-2042-018X[4]
unesp.campusUniversidade Estadual Paulista (Unesp), Instituto de Ciência e Tecnologia, Sorocabapt

Arquivos

Licença do Pacote
Agora exibindo 1 - 1 de 1
Nenhuma Miniatura disponível
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descrição:

Coleções

Artigos - Engenharia Ambiental - Sorocaba